CRS-207: Phase I/II started

Aduro began the open-label, U.S. Phase I/II SEASCAPE trial to evaluate IV CRS-207 plus twice-daily oral

Read the full 165 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE